2025-05-12 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data.  I will present the information in English with numbers first, followed by a brief analysis for each section.

**1. Performance Overview & Comparison with S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company:** Johnson & Johnson - A global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 37.97%
*   **VOO (S&P 500) Cumulative Return:** 87.98%
*   **Absolute Deviation:** -50.0% (JNJ underperformed VOO by 50.0% over the analyzed period).
*   **Deviation Range:** Max: 21.3, Min: -77.2
*   **Relative Deviation:** 27.6 (JNJ's current underperformance relative to VOO is positioned in the lower quartile of its historical deviation range, indicating relatively strong underperformance within its own history).

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 33.0%   | 55.5%   | 1.0%    | 0.1    | 272.4  |
| 2016-2018  | 15.0%   | 10.7%   | -6.0%   | -0.0   | 258.4  |
| 2017-2019  | 25.0%   | 10.7%   | -8.0%   | 0.7    | 300.3  |
| 2018-2020  | 20.0%   | 59.4%   | -10.0%  | 0.5    | 332.8  |
| 2019-2021  | 35.0%   | 59.5%   | -25.0%  | 0.4    | 370.9  |
| 2020-2022  | 8.0%    | 61.3%   | -1.0%   | 0.3    | 393.0  |
| 2021-2023  | -17.0%  | 61.3%   | -38.0%  | 0.4    | 359.3  |
| 2022-2024  | -31.0%  | 61.3%   | -51.0%  | 0.3    | 342.0  |
| 2023-2025  | -1.0%   | 69.7%   | -27.0%  | 0.1    | 371.1  |

**Analysis:** JNJ has significantly underperformed the S&P 500 over the specified period.  The negative alpha values across most periods suggest that JNJ's returns have been consistently lower than what would be expected based on its beta (market sensitivity).  The beta values are relatively low, indicating that JNJ's price movements are less correlated with the overall market.  The MDD suggests a large drawdowns.

**2. Recent Price Action**

*   **Current Price:** 155.66
*   **Last Market Data:** Price: 154.22, Previous Close: 155.66, Change: -0.93
*   **5-Day Moving Average:** 155.71
*   **20-Day Moving Average:** 154.996
*   **60-Day Moving Average:** 159.0438

**Analysis:** The current price is below the 5-day moving average, indicating a recent slight downward trend. The price is also below the 60-day moving average, suggesting a potential weakening in the medium-term.  The negative change in the last market data supports this.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3707 (Low Risk)
*   **RSI:** 44.31
*   **PPO:** 0.1954
*   **Recent (20-day) Relative Deviation Change:** -1.1 (Negative - short-term decline)
*   **Expected Return (%):** -70.5% (Long-term expected outperformance vs. S&P 500 from current point, through dollar-cost averaging)

**Analysis:** The MRI indicates a low-risk environment for JNJ. The RSI is below 50, suggesting that the stock is not overbought. The negative change in relative deviation suggests a short-term underperformance trend. However, the extremely negative expected return suggests a potential long-term dollar cost averaging opportunity for outperformance relative to the S&P 500. The decline in price in `Last-market` of -0.93 indicates some negative short-term pressure.

**4. Recent News & Significant Events**

*   **2025-05-08:** Major business developments, regulatory changes, or market events impacting JNJ.
*   **2025-05-12:** Analysts discussing JNJ's recent performance and outlook.
*   **2025-05-09:** JNJ's stock showing notable volatility.
*   **2025-05-10:** Market experts highlighting both risks and opportunities.

**Analysis:** The recent news indicates that JNJ is experiencing a period of volatility and is subject to analyst scrutiny.  It's crucial to investigate these events further to understand the specific factors driving the stock's movement.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2024-05-01 | 1.35 | 21.38 B$   |
| 2025-04-23 | 1.35 | 21.38 B$   |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated. The most recent EPS is significantly higher than previous quarters, but the earlier entry of 2025-04-23 of  `1.35` should be investigated as it looks like duplicated data. Revenue shows some variability, but the $22B range seems consistent.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |
| 2024-06-30   | $22.45B   | 69.40%        |
| 2024-03-31   | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-03-31   | $78.11B   | 14.08%    |
| 2024-12-31   | $71.49B   | 4.80%     |
| 2024-09-30   | $70.16B   | 3.84%     |
| 2024-06-30   | $71.54B   | 6.55%     |
| 2024-03-31   | $70.02B   | 4.65%     |

**Analysis:** While revenue has remained relatively stable, the profit margin has seen a slight decline in the most recent quarter.  Equity has generally increased, and the return on equity (ROE) has shown significant improvement in the last quarter.

**7. Overall Analysis & Summary**

Based on the provided data, Johnson & Johnson (JNJ) presents a mixed picture.

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the historical period.
*   **Price Trend:** Recent price action suggests a slight downward trend.
*   **Risk:** MRI indicates a low-risk investment environment.
*   **Volatility:** Recent news suggests potential volatility.
*   **Earnings:** Earnings have fluctuated, but revenue has been relatively stable.
*   **Financial Health:** Profit margins are slightly declining, but ROE has seen improvement and Equity is generally increasing.
*   **Long-Term Potential:** Despite recent underperformance, the exceptionally negative expected return suggests a potential opportunity for long-term outperformance vs. the S&P 500 through dollar cost averaging.

**Recommendation:**

Given the underperformance and potential volatility, investors should proceed with caution. Further investigation into the recent news and business developments is necessary.  The potential long-term dollar cost averaging opportunity and the low MRI suggest that JNJ might be worth considering for long-term investors with a higher risk tolerance and willingness to dollar-cost-average.  However, the data points towards weaker performance versus the market and a degree of current uncertainty.
